MEA Foot and Ankle Allograft Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-24
- Report ID: 143386
- Pages: 225
-
Format:
Short Description
Middle East and Africa foot and ankle allografts Market, By Product Type (Allograft Wedges, Allograft Tendons, Allograft Acellular Dermal Matrix, Cartilage Allograft Matrix, Skin Allografts, Amniotic Membranes), Surgery Type (Orthopedic Reconstruction, Cartilage Restoration, Soft Tissue Tendon & Ligament Repair, Wound Care) Procedure (Midfoot Procedures, Hindfoot Procedures), End User (Hospitals, Orthopedic Clinics, Ambulatory Surgical Centers, Academic and Research Institutes, Other End Users) Industry Trends & Forecast to 2029.
Market Definition:
Foot and ankle allografts is the use of digital information and communication technologies, such as computers and mobile devices, to access health care services remotely and helping physicians to in lowering their burden.
The demand for foot and ankle allografts has been increased in market of Middle East and Africa with the increasing geriatric population and chronic diseases. The foot and ankle allografts market is growing due to introduction of innovative products, increasing in technological products and rising disposable income. The market will grow in forecasted period due to exploration of emerging markets, strategic initiatives by market players, increasing healthcare expenditure.
Market Segmentation:
Middle East and Africa foot and ankle allografts market is categorized into four notable segment which is product type, surgery type, procedure and end user..
On the basis of product type, Middle East and Africa foot and ankle allograft market is segmented into allograft wedges, allograft tendons, allograft, acellular dermal matrix, cartilage allograft matrix, skin allografts, and amniotic membranes. In 2022, allograft wedges segment in Middle East and Africa foot and ankle allograft market is expected to growing in the market with the increasing advancement in the technology.
On the basis of surgery type, Middle East and Africa foot and ankle allograft market is segmented into orthopedic reconstruction, cartilage restoration, soft tissue tendon & ligament repair and wound care. In 2022, orthopedic reconstruction segment in Middle East and Africa foot and ankle allograft market is expected to growing in the market with the increasing product launches and rising R&D activities by major market players.
On the basis of procedure, Middle East and Africa foot and ankle allograft market is segmented into midfoot procedures and hind-foot procedures. In 2022, midfoot procedures segment in Middle East and Africa foot and ankle allograft market is expected to grow with the increasing use of foot and ankle allograft and increasing chronic disease Middle East and Africa.
On the basis of end user, Middle East and Africa foot and ankle allograft market is segmented into hospitals, orthopedic clinics, ambulatory surgical centers, academic and research institutes and other end users. In 2022, hospital segment in Middle East and Africa foot and ankle allograft market is expected to growing in the market with the increasing patient population in hospitals
Market Players
The key market players for Middle East and Africa foot and ankle allografts market are listed below:
Johnson & Johnson Services, Inc.,
Integra Lifesciences
CONMED Corporation.
Stryker,
Bioventus,
AlloSource,
Smith Nephew,
Arthrex, Inc.,
Organogenesis Inc.,
TABLE OF CONTENTS
1 INTRODUCTION 31
1.1 OBJECTIVES OF THE STUDY 31
1.2 MARKET DEFINITION 31
1.3 OVERVIEW OF MIDDLE EAST & AFRICA FOOT AND ANKLE ALLOGRAFTS MARKET 31
1.4 LIMITATIONS 33
1.5 MARKETS COVERED 33
2 MARKET SEGMENTATION 36
2.1 MARKETS COVERED 36
2.2 GEOGRAPHICAL SCOPE 37
2.3 YEARS CONSIDERED FOR THE STUDY 38
2.4 CURRENCY AND PRICING 38
2.5 DBMR TRIPOD DATA VALIDATION MODEL 39
2.6 MULTIVARIATE MODELLING 42
2.7 END USER LIFELINE CURVE 42
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 43
2.9 DBMR MARKET POSITION GRID 44
2.10 MARKET APPLICATION COVERAGE GRID 45
2.11 VENDOR SHARE ANALYSIS 46
2.12 SECONDARY SOURCES 47
2.13 ASSUMPTIONS 47
3 EXECUTIVE SUMMARY 48
4 PREMIUM INSIGHTS 50
4.1 PORTERS FIVE FORCES 51
5 INDUSTRIAL INSIGHTS: 52
5.1 CONCLUSION: 52
6 MIDDLE EAST & AFRICA FOOT AND ANKLE ALLOGRAFTS MARKET: REGULATIONS 53
6.1 U.S. 54
6.2 CANADA 55
6.3 EUROPE 55
7 MARKET OVERVIEW 57
7.1 DRIVERS 59
7.1.1 GROWING GERIATRIC POPULATION 59
7.1.2 INCREASE IN PREVALENCE OF MUSCULOSKELETAL DISORDER 59
7.1.3 INCREASE IN HEALTHCARE EXPENDITURE 60
7.1.4 INCREASE IN STRATEGIC INITIATIVES BY MAJOR MARKET PLAYERS 61
7.2 RESTRAINTS 62
7.2.1 STRINGENT REGULATORY 62
7.2.2 COMPLICATION AND RISK OF ALLOGRAFTS 62
7.3 OPPORTUNITIES 63
7.3.1 INCREASE IN NUMBER OF SPORTS INJURIES 63
7.3.2 RISE IN AWARENESS INITIATIVES ABOUT THE ALLOGRAFT PROCEDURE: 64
7.3.3 INCREASING RISK OF OSTEOPOROSIS AND OSTEOARTHRITIS: 65
7.4 CHALLENGES 66
7.4.1 COVID-19 IMPACT ON MIDDLE EAST & AFRICA FOOT AND ANKLE ALLOGRAFTS MARKET 66
7.4.2 ALLOGRAFT IS OFTEN CONSIDERED TOO EXPENSIVE IN LOW-INCOME TO MIDDLE-INCOME COUNTRIES: 67
7.4.3 HIGHER ADOPTION OF ALTERNATIVE THERAPIES FOR THE TREATMENT OF FOOT AND ANKLE DISORDERS: 68
8 MIDDLE EAST & AFRICA FOOT AND ANKLE ALLOGRAFTS MARKET, BY PRODUCT TYPE 69
8.1 OVERVIEW 70
8.2 ALLOGRAFT WEDGES 73
8.3 ALLOGRAFT TENDONS 73
8.4 ALLOGRAFT ACELLULAR DERMAL MATRIX 74
8.5 CARTILAGE ALLOGRAFT MATRIX 75
8.6 SKIN ALLOGRAFTS 76
8.7 AMNIOTIC MEMBRANES 77
9 MIDDLE EAST & AFRICA FOOT AND ANKLE ALLOGRAFTS MARKET, BY SURGERY TYPE 78
9.1 OVERVIEW 79
9.2 ORTHOPEDIC RECONSTRUCTION 82
9.2.1 NON-UNIONS FRACTURES 83
9.2.2 ARTHRODESIS PROCEDURES 83
9.2.3 OSTEOTOMY PROCEDURES 83
9.3 CARTILAGE RESTORATION 83
9.3.1 TALAR DOME REPAIR 84
9.3.2 TIBIAL PLAFOND REPAIR 84
9.3.3 METATARSAL REPAIR 84
9.3.4 TALONAVICULAR JOINT REPAIR 84
9.3.5 SUBTALAR JOINT REPAIR 84
9.4 SOFT TISSUE TENDON & LIGAMENT REPAIR 84
9.4.1 TENDON AUGMENTATION 85
9.4.2 LIGAMENT REPAIR 85
9.4.3 FAT PAD REPLACEMENT 85
9.4.4 PLANTAR PLATE REPAIR 86
9.5 WOUND CARE 86
9.5.1 ANKLE ULCER TREATMENT 87
9.5.2 NEUROPATHIC FOOT ULCER TREATMENT 87
10 MIDDLE EAST & AFRICA FOOT AND ANKLE ALLOGRAFTS MARKET, BY PROCEDURE 88
10.1 OVERVIEW 89
10.2 MIDFOOT PROCEDURES 92
10.2.1 CUBOID FRACTURE 93
10.2.2 FIRST TARSOMETATARSAL JOINT ARTHRODESIS 93
10.2.3 MEDIAL COLUMN ARTHRODESIS 93
10.2.4 LISFRANC 93
10.2.5 MEDIAL CUNEIFORM DORSAL OPENING WEDGE (COTTON) OSTEOTOMY 93
10.2.6 NAVICULAR CUNEIFORM ARTHRODESIS 93
10.2.7 NAVICULAR FRACTURE 93
10.2.8 OTHER MIDFOOT PROCEDURES 93
10.3 HIND-FOOT PROCEDURES 93
10.3.1 CALCANEAL FRACTURE 94
10.3.2 LATERAL COLUMN LENGTHENING 94
10.3.3 TALONAVICULAR JOINT ARTHRODESIS 95
10.3.4 TRIPLE ARTHRODESIS 95
10.3.5 OTHER HINDFOOT PROCEDURES 95
11 MIDDLE EAST & AFRICA FOOT AND ANKLE ALLOGRAFTS MARKET, BY END USER 96
11.1 OVERVIEW 97
11.2 HOSPITALS 100
11.3 ORTHOPEDIC CLINICS 100
11.4 AMBULATORY SURGICAL CENTERS 101
11.5 ACADEMIC AND RESEARCH INSTITUTES 102
11.6 OTHER END USERS 103
12 MIDDLE EAST & AFRICA FOOT AND ANKLE ALLOGRAFT MARKET, BY REGION 104
12.1 MIDDLE EAST AND AFRICA 105
12.1.1 SOUTH AFRICA 113
12.1.2 SAUDI ARABIA 116
12.1.3 U.A.E. 119
12.1.4 ISRAEL 122
12.1.5 EGYPT 125
12.1.6 REST OF MIDDLE EAST AND AFRICA 128
13 MIDDLE EAST & AFRICA FOOT AND ANKLE ALLOGRAFTS MARKET: COMPANY LANDSCAPE 129
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 129
14 SWOT ANALYSIS 130
15 COMPANY PROFILE 131
15.1 LIFENET HEALTH 131
15.1.1 COMPANY SNAPSHOT 131
15.1.2 COMPANY SHARE ANALYSIS 131
15.1.3 PRODUCT PORTFOLIO 132
15.1.4 RECENT DEVELOPMENTS 133
15.1.4.1 CONFERENCE 133
15.1.4.2 PRODUCT LAUNCH 134
15.2 ZIMMER BIOMET 135
15.2.1 COMPANY SNAPSHOT 135
15.2.2 REVENUE ANALYSIS 135
15.2.3 COMPANY SHARE ANALYSIS 136
15.2.4 PRODUCT PORTFOLIO 136
15.2.5 RECENT DEVELOPMENT 136
15.2.5.1 PARTNERSHIP 136
15.3 JOHNSON & JOHNSON SERVICES, INC. 137
15.3.1 COMPANY SNAPSHOT 137
15.3.2 REVENUE ANALYSIS 137
15.3.3 COMPANY SHARE ANALYSIS 138
15.3.4 PRODUCT PORTFOLIO 138
15.3.5 RECENT DEVELOPMENTS 138
15.3.5.1 EVENT 138
15.3.5.2 PRODUCT LAUNCH 138
15.4 INTEGRA LIFESCIENCES 139
15.4.1 COMPANY SNAPSHOT 139
15.4.2 REVENUE ANALYSIS 139
15.4.3 COMPANY SHARE ANALYSIS 140
15.4.4 PRODUCT PORTFOLIO 140
15.4.5 RECENT DEVELOPMENTS 140
15.4.5.1 POSITIVE CLINICAL OUTCOME 140
15.4.5.2 AGREEMENT 140
15.4.5.3 ACQUISITION 141
15.5 CONMED CORPORATION (2022) 142
15.5.1 COMPANY SNAPSHOT 142
15.5.2 REVENUE ANALYSIS 142
15.5.3 COMPANY SHARE ANALYSIS 143
15.5.4 PRODUCT PORTFOLIO 143
15.5.5 RECENT DEVELOPMENT 144
15.5.5.1 ACQUISITION 144
15.6 ALLOSOURCE 145
15.6.1 COMPANY SNAPSHOT 145
15.6.2 PRODUCT PORTFOLIO 145
15.6.3 RECENT DEVELOPMENT 146
15.6.3.1 PRODUCT LAUNCH 146
15.7 ALON SOURCE GROUP 147
15.7.1 COMPANY SNAPSHOT 147
15.7.2 PRODUCT PORTFOLIO 147
15.7.3 RECENT DEVELOPMENT 147
15.8 AMNIOX MEDICAL INC. 148
15.8.1 COMPANY SNAPSHOT 148
15.8.2 PRODUCT PORTFOLIO 148
15.8.3 RECENT DEVELOPMENT 148
15.8.3.1 PARTNERSHIP 148
15.9 ARTHREX 149
15.9.1 COMPANY SNAPSHOT 149
15.9.2 PRODUCT PORTFOLIO 149
15.9.3 RECENT DEVELOPMENT 149
15.9.3.1 PRODUCT LAUNCH 149
15.10 BIOVENTUS 150
15.10.1 COMPANY SNAPSHOT 150
15.10.2 REVENUE ANALYSIS 150
15.10.3 PRODUCT PORTFOLIO 151
15.10.4 RECENT DEVELOPMENT 151
15.10.4.1 CO-DEVELOPMENT 151
15.11 BONE BANK ALLOGRAFTS 152
15.11.1 COMPANY SNAPSHOT 152
15.11.2 PRODUCT PORTFOLIO 152
15.11.3 RECENT DEVELOPMENTS 152
15.11.3.1 PARTNERSHIP 152
15.12 GLOBUS MEDICAL 153
15.12.1 COMPANY SNAPSHOT 153
15.12.2 REVENUE ANALYSIS 153
15.12.3 PRODUCT PORTFOLIO 154
15.12.4 RECENT DEVELOPMENTS 154
15.12.4.1 M&A 154
15.13 INSTITUT STRAUMANN 155
15.13.1 COMPANY SNAPSHOT 155
15.13.2 REVENUE ANALYSIS 155
15.13.3 PRODUCT PORTFOLIO 156
15.13.4 RECENT DEVELOPMENT 156
15.14 JRF ORTHO 157
15.14.1 COMPANY SNAPSHOT 157
15.14.2 PRODUCT PORTFOLIO 157
15.14.3 RECENT DEVELOPMENT 158
15.14.3.1 PARTNERSHIP 158
15.15 NVISION BIOMEDICAL TECHNOLOGIES. 159
15.15.1 COMPANY SNAPSHOT 159
15.15.2 PRODUCT PORTFOLIO 159
15.15.3 RECENT DEVELOPMENT 159
15.15.3.1 ACQUISITION 159
15.16 PARAGON28, INC. 160
15.16.1 COMPANY SNAPSHOT 160
15.16.2 REVENUE ANALYSIS 160
15.16.3 PRODUCT PORTFOLIO 161
15.16.4 RECENT DEVELOPMENT 161
15.16.4.1 ACQUISITION 161
15.17 ORGANOGENESIS INC 162
15.17.1 COMPANY SNAPSHOT 162
15.17.2 REVENUE ANALYSIS 162
15.17.3 PRODUCT PORTFOLIO 163
15.17.4 RECENT DEVELOPMENTS 163
15.17.4.1 CONFERENCE 163
15.17.4.2 ACQUISITION 163
15.18 SMITH + NEPHEW 164
15.18.1 COMPANY SNAPSHOT 164
15.18.2 REVENUE ANALYSIS 164
15.18.3 PRODUCT PORTFOLIO 165
15.18.4 RECENT DEVELOPMENTS 165
15.18.4.1 EVENT 165
15.18.4.2 ACQUISITION 165
15.19 STRYKER 166
15.19.1 COMPANY SNAPSHOT 166
15.19.2 REVENUE ANALYSIS 166
15.19.3 PRODUCT PORTFOLIO 167
15.19.4 RECENT DEVELOPMENT 167
16 QUESTIONNAIRE 168
17 RELATED REPORTS 171
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
